IGFBP-2 partly mediates the early metabolic improvements caused by bariatric surgery.
BPD-DS
RYGB
bariatric surgery
binding protein
humans
insulin-like growth factor
metabolism
mice
patients
sleeve gastrectomy
type 2 diabetes
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
20 04 2021
20 04 2021
Historique:
received:
01
06
2020
revised:
21
12
2020
accepted:
23
03
2021
entrez:
5
5
2021
pubmed:
6
5
2021
medline:
6
5
2021
Statut:
epublish
Résumé
Insulin-like growth factor-binding protein (IGFBP)-2 is a circulating biomarker of cardiometabolic health. Here, we report that circulating IGFBP-2 concentrations robustly increase after different bariatric procedures in humans, reaching higher levels after biliopancreatic diversion with duodenal switch (BPD-DS) than after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG). This increase is closely associated with insulin sensitization. In mice and rats, BPD-DS and RYGB operations also increase circulating IGFBP-2 levels, which are not affected by SG or caloric restriction. In mice,
Identifiants
pubmed: 33948578
doi: 10.1016/j.xcrm.2021.100248
pii: S2666-3791(21)00064-1
pmc: PMC8080239
doi:
Substances chimiques
IGFBP2 protein, human
0
Insulin-Like Growth Factor Binding Protein 2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
100248Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK092587
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM118430
Pays : United States
Organisme : CIHR
ID : PJT-148550
Pays : Canada
Organisme : CIHR
ID : MOP-97947
Pays : Canada
Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
A.C.C. has received consultant fees from Janssen (2017 and 2018), Novartis (2018), Novo Nordisk (2018), HLS Therapeutics (2019), and Eli Lilly (2020). A.-M.C. has received consultant fees from Pfizer (2017). A.T. received consulting fees from Novo Nordisk and Bausch Health. A.T. and L.B. are the recipients of research grant support from Johnson & Johnson Medical Companies and Medtronic for studies on bariatric surgery and the Research Chair in Bariatric and Metabolic Surgery, respectively, at l’Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) and Laval University. All of the other authors reported no competing financial interests in relation to the work described herein.
Références
Mol Cell Endocrinol. 2012 Jul 6;358(1):63-8
pubmed: 22410287
Sci Rep. 2016 Mar 24;6:23665
pubmed: 27009398
Cell Metab. 2019 Nov 5;30(5):855-864.e3
pubmed: 31588013
Atherosclerosis. 2014 Dec;237(2):645-51
pubmed: 25463100
Horm Metab Res. 2010 Oct;42(11):787-91
pubmed: 20730703
Endocrinology. 1999 Dec;140(12):5488-96
pubmed: 10579311
Cytokine Growth Factor Rev. 2015 Jun;26(3):329-46
pubmed: 25544066
Nutrients. 2019 Mar 10;11(3):
pubmed: 30857366
Obes Surg. 2003 Apr;13(2):258-62
pubmed: 12740135
Cell Mol Gastroenterol Hepatol. 2019;8(2):235-246
pubmed: 31075353
Can J Cardiol. 2015 Feb;31(2):153-66
pubmed: 25661550
J Biol Chem. 2015 May 1;290(18):11578-90
pubmed: 25787077
Endocrinology. 2014 Mar;155(3):716-25
pubmed: 24424049
PLoS One. 2013;8(1):e52922
pubmed: 23326365
Endocrinology. 2013 Nov;154(11):4146-57
pubmed: 23981772
Gastroenterology. 2019 Mar;156(4):1041-1051.e4
pubmed: 30445014
Cell Rep. 2016 May 3;15(5):944-950
pubmed: 27117413
J Clin Endocrinol Metab. 2008 Jul;93(7):2479-85
pubmed: 18430778
Diabetes. 2007 Feb;56(2):285-94
pubmed: 17259371
Nutr Clin Pract. 2010 Apr;25(2):175-82
pubmed: 20413698
Am J Physiol Regul Integr Comp Physiol. 2014 Mar 1;306(5):R352-62
pubmed: 24430883
Int J Obes (Lond). 2015 May;39(5):798-805
pubmed: 25349056
Obes Surg. 2016 Sep;26(9):2173-2182
pubmed: 26781597
Am J Physiol Endocrinol Metab. 2015 Aug 15;309(4):E409-17
pubmed: 26105006
Surg Obes Relat Dis. 2009 Jan-Feb;5(1):43-7
pubmed: 18440876
J Clin Endocrinol Metab. 2015 Mar;100(3):E396-406
pubmed: 25536209
Obesity (Silver Spring). 2010 Jun;18(6):1085-91
pubmed: 20057364
Obesity (Silver Spring). 2012 Jul;20(7):1469-73
pubmed: 22522884
Obes Surg. 2014 Nov;24(11):1843-9
pubmed: 24839191
Cell Metab. 2017 Feb 7;25(2):335-344
pubmed: 28065827
N Engl J Med. 2004 Dec 23;351(26):2683-93
pubmed: 15616203
Obes Surg. 2016 May;26(5):957-65
pubmed: 26259981
Growth Horm IGF Res. 2008 Dec;18(6):506-16
pubmed: 18550406
Endocrine. 2019 Jul;65(1):86-93
pubmed: 30945111
Diabetes. 2001 Jun;50(6):1402-13
pubmed: 11375342
Trends Endocrinol Metab. 2009 May;20(4):153-62
pubmed: 19349193
Nature. 2014 May 8;509(7499):183-8
pubmed: 24670636
Cell Rep. 2020 Oct 27;33(4):108270
pubmed: 33113371
Ann Surg. 2006 Nov;244(5):741-9
pubmed: 17060767
BMC Neurosci. 2013 Dec 21;14:158
pubmed: 24359611
Protein J. 2013 Feb;32(2):138-42
pubmed: 23397525
Obes Surg. 2017 Sep;27(9):2424-2433
pubmed: 28386755
Circulation. 2011 Apr 19;123(15):1683-701
pubmed: 21403092
Obesity (Silver Spring). 2006 Feb;14(2):273-9
pubmed: 16571853
Cell Metab. 2010 Jan;11(1):11-22
pubmed: 20074524
Diabetes. 2017 Nov;66(11):2743-2755
pubmed: 28835473
Exp Clin Endocrinol Diabetes. 2006 Jul;114(7):371-6
pubmed: 16915540
Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):107-115
pubmed: 30580566
Nat Med. 2012 Jun;18(6):950-5
pubmed: 22610279
Curr Opin Clin Nutr Metab Care. 2006 Jul;9(4):497-507
pubmed: 16778583
Endocrinology. 2015 Apr;156(4):1316-29
pubmed: 25646712
Am J Med. 2016 Sep;129(9):952-9
pubmed: 26899751
Mol Metab. 2019 Jul;25:64-72
pubmed: 31126840
Mol Metab. 2013 Dec 11;3(2):191-201
pubmed: 24634822
J Biol Chem. 2013 Mar 8;288(10):7117-26
pubmed: 23329830
Obes Surg. 2018 Oct;28(10):3227-3236
pubmed: 29770924
Exp Gerontol. 2014 Oct;58:154-8
pubmed: 25106097
Diabetes. 2013 Jul;62(7):2380-5
pubmed: 23434938
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
Clin Nutr. 2017 Jun;36(3):861-868
pubmed: 27188262
Mol Metab. 2016 Aug 16;5(10):1006-1014
pubmed: 27689013
Oxid Med Cell Longev. 2017;2017:3035184
pubmed: 29422987
Front Endocrinol (Lausanne). 2019 Nov 22;10:822
pubmed: 31824433